Patients with advanced-stage neuroendocrine tumours (NETs) have limited treatment options following disease progression after 1–2 lines of systemic therapy. Now, newly published data from the phase III CABINET trial, simultaneously presented at the ESMO Congress 2024, demonstrate the efficacy of cabozantinib in this setting.

In CABINET, patients with locally advanced or metastatic well or moderately differentiated extrapancreatic (n = 203) or pancreatic (n = 95) NETs previously treated with at least one FDA-approved systemic therapy were randomly assigned, 2:1, to either cabozantinib or placebo. Most patients had received ¹⁷⁷Lu-dotatate (~59%) and/or everolimus (~72%), and ~26% of those with pancreatic NETs had received sunitinib. Progression-free survival (PFS) was the primary end point.

晚期神经内分泌肿瘤 （NET） 患者在接受 1-2 线全身治疗后疾病进展后的治疗选择有限。现在，在 2024 年 ESMO 年会上同步公布的 III 期 CABINET 试验新发表的数据证明了卡博替尼在这种情况下的疗效。

在 CABINET 中，既往接受过至少一种 FDA 批准的全身治疗且患有局部晚期或转移性良好或中度分化胰腺外 （n = 203） 或胰腺 （n = 95） NET 的患者以 2：1 的比例随机分配到卡博替尼组或安慰剂组。大多数患者接受了 ¹⁷⁷个 Lu-dotatate （~59%） 和/或依维莫司 （~72%） 治疗，~26% 的胰腺 NET 患者接受了舒尼替尼治疗。无进展生存期 （PFS） 是主要终点。